DotLab announces three granted patents for its non-invasive test for endometriosis, DotEndo™
Retrieved on:
Friday, August 19, 2022
Laboratory, Machine learning, Association, Biomarker, Endometriosis, Invention, Trial of the century, CEO, Algorithm, Diagnosis, Technology, Patent, Society for Maternal-Fetal Medicine, Disease, Saliva, EMPOWER, Blood, United States Patent and Trademark Office, American Journal, Patient, Computational biology, Society, RNA, Gynaecology, Medicine, Obstetrical Society of London, Biology, News, National Association of Professors of Hebrew, MicroRNA, Health, Pharmaceutical industry, Obstetrics
Via its clinical studies, DotLab has pioneered medical tests enabled by single-stranded, non-coding RNAs called microRNAs in circulating body fluids such as blood and saliva.
Key Points:
- Via its clinical studies, DotLab has pioneered medical tests enabled by single-stranded, non-coding RNAs called microRNAs in circulating body fluids such as blood and saliva.
- The inventions embodied in the portfolio of granted patents U.S. Patent No.
- 11,315,660 B2 also include the company's proprietary machine learning algorithms to detect, predict, diagnose, and monitor the presence or absence of the disease.
- EMPOWER is the most robust clinical study of its type ever performed, making it an excellent foundation for thecommercial test.